Full-Time

HSE Specialist

Posted on 6/16/2025

Deadline 6/25/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

No salary listed

Senior

Greendale, WI, USA

May require occasional travel to other Sanofi sites

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree in environmental health and safety, Occupational Health, Chemistry, or related scientific discipline
  • 5+ years of HSE experience within the pharmaceutical or related regulated industry
  • Demonstrated success in implementing and transforming HSE programs
  • Track record of influencing senior stakeholders and driving organizational change
  • Experience managing complex projects with significant business impact
  • Certification in relevant HSE disciplines (NEBOSH, CSP, CIH, etc.)
  • Experience with Process safety across pharmaceutical manufacturing processes
  • Strategic thinking and ability to align HSE initiatives with business priorities
  • Knowledge of relevant HSE regulations and standards (e.g., OSHA/HSE regulations, ISO 14001, ISO 45001)
  • Experience presenting to executive leadership and external stakeholder
  • Strong understanding of pharmaceutical HSE hazards and control measures
  • Knowledge of chemical safety, biological safety, and pharmaceutical containment principles
  • Proficiency in leveraging AI and advanced digital tools for data analysis, visualization, and reporting of HSE metrics and trends
  • Excellent communication and interpersonal skills for effective collaboration with all levels of the organization
  • Strong analytical and problem-solving abilities
  • Ability to influence and drive cultural change around safety and security
  • Proficiency in HSE management systems and Microsoft Office suite
Responsibilities
  • Serve as a strategic advisor to site leadership on HSE matters and regulatory compliance
  • Represent the site at corporate HSE forums and with regulatory authorities
  • Develop and execute long-term HSE strategy aligned with business objectives
  • Manage significant HSE budgets and resource allocation within a discipline of Health, Safety, Environment & Security
  • Develop, implement, and maintain site HSE management systems in compliance with corporate standards and regulatory requirements
  • Conduct regular HSE risk assessments and safety audits across pharmaceutical manufacturing operations
  • Lead incident investigations and implement corrective and preventive actions
  • Chair and document HAZOP and HAZID assessments for pharmaceutical processes and equipment
  • Provide HSE expertise for change management processes, including review and approval of modifications from an EHS perspective
  • Monitor and evaluate environmental compliance, including waste management, emissions control, and sustainability initiatives
  • Develop and deliver HSE training programs for employees at all levels
  • Prepare and maintain required HSE documentation and regulatory reports
  • Collaborate with cross-functional teams to integrate HSE considerations into new product introductions and manufacturing campaigns
  • Support emergency response planning and preparedness activities
  • Promote a positive safety culture through engagement with employees and management
  • Monitor HSE performance metrics and drive continuous improvement initiatives
  • Participate in the development and implementation of site security protocols and procedures
  • Conduct security risk assessments to identify vulnerabilities in physical and operational security
  • Ensure compliance with relevant security regulations and standards for pharmaceutical facilities
  • Coordinate security awareness training for employees and contractors
  • Monitor and report on security performance metrics and compliance indicators
Desired Qualifications
  • Experience with security management systems and physical security controls is advantageous

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments worldwide. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and adapt to different regulatory environments. The company's goal is to enhance health outcomes and improve the quality of life for people globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's Q1 2025 profit grew by 20%, indicating strong financial performance.
  • The integration of AI in R&D accelerates drug discovery and reduces costs.
  • mRNA technology expansion offers new drug development opportunities for Sanofi.

What critics are saying

  • Increased competition in immunology may impact Sanofi's market share.
  • Potential regulatory delays could affect the launch of new drugs like tolebrutinib.
  • Acquisitions may lead to integration challenges and operational disruptions.

What makes Sanofi unique

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The on-body injector for Sarclisa offers a novel delivery method for multiple myeloma.
  • Dupixent's approval for chronic spontaneous urticaria marks a significant therapeutic advancement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.